4.7 Article

Mitogen-Inducible Gene-6 Is a Multifunctional Adaptor Protein with Tumor Suppressor-Like Activity in Papillary Thyroid Cancer

期刊

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 96, 期 3, 页码 E554-E565

出版社

ENDOCRINE SOC
DOI: 10.1210/jc.2010-1800

关键词

-

资金

  1. Department of Surgery, Brigham and Women's Hospital

向作者/读者索取更多资源

Context: Low tumoral expression of mitogen-inducible gene-6 (Mig-6) is associated with papillary thyroid cancer (PTC) recurrence after thyroidectomy. Objective: We hypothesize that Mig-6 behaves as a tumor suppressor in PTC. Design: Mig-6 expression and promoter methylation status were compared in 31 PTC specimens with matched normal thyroid tissue from the same patient. The impact of Mig-6 loss and gain of function on nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) activation, global tyrosine kinase phosphorylation, and cellular invasion was determined in vitro. Results: Mig-6 protein was abundant in all normal thyroid specimens, whereas 77% of PTC had low Mig-6 expression. Mig-6 promoter methylation was found in 79% of PTC with low Mig-6 expression. Low Mig-6 expression in PTC specimens was associated with low NF-kappa B activity but high levels of epidermal growth factor receptor (EGFR) and ERK phosphorylation. Mig-6 expression inversely correlated with PTC size but had no association with other clinicopathological variables including age, extrathyroidal extension, lymphovascular invasion, or histological subtype. Mig-6 knockdown in thyroid cancer cell lines resulted in EGFR phosphorylation and diminished NF-kappa B activity, whereas Mig-6 overexpression had the opposite effects. Mig-6 knock down activated ErbB2, Met, and Src phosphorylation. Furthermore, Mig-6 regulated ERK phosphorylation independent from its effects on EGFR. Mig-6 knockdown promoted cellular proliferation, as determined by clonogenic survival. Lastly, Mig-6 knockdown increased matrix metalloproteinase-2 and -9 activities and increased cellular invasion. Conclusions: Mig-6 has tumor suppressor-like activity in PTC. In vivo studies are required to confirm that Mig-6 is a putative tumor suppressor in PTC, and future studies should investigate the utility of Mig-6 as a diagnostic marker. (J Clin Endocrinol Metab 96: E554-E565, 2011)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据